本文選題：冠心病 + 經(jīng)皮冠狀動(dòng)脈介入治療�。� 參考：《中國(guó)藥房》2017年24期

【摘要】：目的:探討通心絡(luò)膠囊對(duì)冠心病患者經(jīng)皮冠狀動(dòng)脈介入治療(PCI)術(shù)后血清親環(huán)素A(CyPA)和基質(zhì)金屬蛋白酶9(MMP-9)的影響。方法:擬行PCI術(shù)的115例冠心病患者隨機(jī)分為對(duì)照組(59例)和觀察組(56例)。對(duì)照組患者給予常規(guī)治療;觀察組患者在對(duì)照組治療的基礎(chǔ)上于術(shù)后第1天開始口服通心絡(luò)膠囊0.78 g,每日3次,連用6個(gè)月。觀察兩組患者手術(shù)前后的CyPA、MMP-9水平及不良反應(yīng)發(fā)生情況。結(jié)果:術(shù)前,兩組患者血清CyPA、MMP-9水平比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者術(shù)后1 d、1個(gè)月及對(duì)照組患者術(shù)后6個(gè)月CyPA水平均顯著高于同組術(shù)前,但觀察組術(shù)后1、6個(gè)月顯著低于對(duì)照組,且隨時(shí)間延長(zhǎng)逐漸降低,差異均有統(tǒng)計(jì)學(xué)意義(P0.05);術(shù)后1 d兩組間及觀察組術(shù)后6個(gè)月CyPA水平與術(shù)前比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者術(shù)后1 d、1個(gè)月MMP-9水平均顯著高于同組術(shù)前,但觀察組顯著低于對(duì)照組,且隨時(shí)間延長(zhǎng)逐漸降低,差異均有統(tǒng)計(jì)學(xué)意義(P0.05);兩組患者術(shù)后6個(gè)月MMP-9水平與術(shù)前比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者不良反應(yīng)發(fā)生率比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:在常規(guī)治療的基礎(chǔ)上,通心絡(luò)膠囊可顯著降低冠心病患者PCI術(shù)后的CyPA、MMP-9水平,且未增加不良反應(yīng)的發(fā)生。
[Abstract]:Objective: to investigate the effect of Tongxinluo capsule (TXL) on serum cyclophile Acycline (Acyclin) and matrix metalloproteinase 9 (MMP-9) after percutaneous coronary intervention (PCI) in patients with coronary heart disease (CHD). Methods: one hundred and fifteen patients with coronary heart disease were randomly divided into control group (n = 59) and observation group (n = 56). The patients in the control group were given routine treatment, and the patients in the observation group were given Tongxinluo capsule 0.78 g on the first day after operation, 3 times a day for 6 months. The level of MMP-9 and the incidence of adverse reactions were observed before and after operation. Results: there was no significant difference between the two groups in the serum levels of CyPA-MMP-9 before operation (P 0.05). The level of CyPA in the two groups was significantly higher than that in the control group at 1 day, 1 month and 6 months after operation, but the level of CyPA in the observation group was significantly lower than that in the control group at 1 and 6 months after operation, and decreased gradually with the prolongation of time. There was no significant difference in CyPA level between the two groups and 6 months after operation, and there was no significant difference between the two groups on the 1st day after operation and 6 months after operation (P 0.05). The level of MMP-9 in the two groups was significantly higher than that in the same group at 1 day and 1 month after operation, but the level of MMP-9 in the observation group was significantly lower than that in the control group, and gradually decreased with the prolongation of time, the difference being statistically significant (P 0.05), the level of MMP-9 in the two groups at 6 months after operation was compared with that before operation. The difference was not statistically significant (P 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P 0.05). Conclusion: Tongxinluo capsule can significantly reduce the level of CyPA-MMP-9 in patients with coronary heart disease after PCI, and does not increase the incidence of adverse reactions on the basis of routine treatment.
【作者單位】： 宣城市人民醫(yī)院;
【分類號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 馮俊平;范謙;繆國(guó)斌;張麟;;通心絡(luò)膠囊聯(lián)合西藥治療慢性充血性心力衰竭42例[J];中醫(yī)雜志;2007年06期

2 羅國(guó)華;;通心絡(luò)膠囊聯(lián)合西藥治療冠心病不穩(wěn)定型心絞痛的臨床療效[J];求醫(yī)問藥(下半月);2013年11期

3 張映琦,周華東;通心絡(luò)膠囊治療頸動(dòng)脈粥樣硬化的療效觀察[J];中國(guó)醫(yī)院藥學(xué)雜志;2001年10期

4 劉萬(wàn)鋒;溫宏春;;通心絡(luò)膠囊治療慢性收縮性心力衰竭療效觀察[J];新中醫(yī);2012年10期

5 張紅斌;趙明;張曉明;張巍;楊建國(guó);;通心絡(luò)膠囊對(duì)冠狀動(dòng)脈慢血流患者腦循環(huán)的影響[J];河北中醫(yī);2014年01期

6 李燕屏,劉炳煩,江慧琳,張慶光,劉國(guó)斌;通心絡(luò)膠囊對(duì)肺心病患者血漿內(nèi)皮素、降鈣素基因相關(guān)肽的影響[J];中華急診醫(yī)學(xué)雜志;2003年07期

7 金筠菁,何彬;通心絡(luò)膠囊治療老年冠心病心絞痛臨床療效觀察[J];中國(guó)民康醫(yī)學(xué);2003年09期

8 李淑艷;湯琪;;通心絡(luò)膠囊聯(lián)合西藥治療心臟X綜合征36例臨床觀察[J];云南中醫(yī)中藥雜志;2009年11期

9 張雪琪,潘志紅,徐燕玲,王一塵;通心絡(luò)膠囊治療老年冠心病心絞痛的臨床觀察[J];老年醫(yī)學(xué)與保健;2000年02期

10 劉炳煩,江慧琳,李燕屏;通心絡(luò)膠囊對(duì)肺心病患者血液流變學(xué)的影響及意義[J];嶺南急診醫(yī)學(xué)雜志;2004年02期

相關(guān)會(huì)議論文 前4條

1 尤士杰;楊躍進(jìn);陳可冀;吳永健;荊志成;張健;胡奉環(huán);白東峰;唐熠達(dá);高潤(rùn)霖;;通心絡(luò)膠囊在急性心肌梗死血運(yùn)重建后的有效性和安全性研究[A];中華醫(yī)學(xué)會(huì)心血管病分會(huì)第八次全國(guó)心血管病學(xué)術(shù)會(huì)議匯編[C];2004年

2 陳章強(qiáng);洪浪;尹秋林;王洪;陸林祥;賴珩莉;;通心絡(luò)膠囊對(duì)急性冠狀動(dòng)脈綜合征患者介入治療后不同時(shí)期血小板活化及血管內(nèi)皮功能以及預(yù)后的影響[A];中華醫(yī)學(xué)會(huì)第十五次全國(guó)心血管病學(xué)大會(huì)論文匯編[C];2013年

3 尤士杰;楊躍進(jìn);陳可冀;吳永健;荊志成;張健;胡奉環(huán);白東峰;唐熠達(dá);高潤(rùn)霖;;通心絡(luò)膠囊在急性心肌梗死血運(yùn)重建后的有效性和安全性研究[A];中華醫(yī)學(xué)會(huì)心血管病學(xué)分會(huì)第十次全國(guó)心血管病學(xué)術(shù)會(huì)議匯編[C];2008年

4 王雪樵;劉傳垠;;通心絡(luò)膠囊聯(lián)合阿司匹林治療穩(wěn)定性心絞痛30例療效觀察[A];首屆中西醫(yī)血管病學(xué)大會(huì)論文匯編[C];2013年

相關(guān)重要報(bào)紙文章 前5條

1 胡春松;通心絡(luò)膠囊[N];家庭醫(yī)生報(bào);2005年

2 黃福東;通心絡(luò)膠囊的深入研究中標(biāo)國(guó)家自然科學(xué)基金課題[N];科技日?qǐng)?bào);2003年

3 ;通心絡(luò)膠囊研究被列為國(guó)家自然科學(xué)基金課題[N];中國(guó)中醫(yī)藥報(bào);2003年

4 長(zhǎng)發(fā);開創(chuàng)治療心腦血管病全新途徑[N];醫(yī)藥經(jīng)濟(jì)報(bào);2000年

5 樂 水;血管內(nèi)皮功能障礙研究取得新進(jìn)展[N];中國(guó)中醫(yī)藥報(bào);2002年

相關(guān)碩士學(xué)位論文 前1條

1 馮靜;通心絡(luò)膠囊對(duì)頸動(dòng)脈粥樣硬化患者血脂和hs-CRP水平的影響[D];遼寧中醫(yī)藥大學(xué);2016年

，

本文編號(hào)：1827822